FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

61 results

alecensa
(ALECTINIB HYDROCHLORIDE)
Genentech, Inc.
Usage: ALECENSA is indicated for the adjuvant treatment of adults with resected ALK-positive non-small cell lung cancer (NSCLC), and for the treatment of adult patients with metastatic ALK-positive NSCLC, both as detected by an FDA-approved test.
alunbrig
(brigatinib)
Takeda Pharmaceuticals America, Inc.
Usage: ALUNBRIG is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), confirmed by an FDA-approved test.
augtyro
(repotrectinib)
E.R. Squibb & Sons, L.L.C.
Usage: AUGTYRO is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with NTRK gene fusion-positive solid tumors that are advanced or metastatic, or where surgery poses severe risk, and have limited treatment options.
ayvakit
(avapritinib)
Blueprint Medicines Corporation
Usage: AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM). It is not recommended for patients with platelet counts below 50 × 10⁹/L.
balversa
(Erdafitinib)
Janssen Products LP
Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with FGFR3 genetic alterations, following progression on at least one prior systemic therapy. Selection of patients must utilize an FDA-approved companion diagnostic. It is not recommended for those eligible for PD-1 or PD-L1 inhibitors.
bosulif
(Bosutinib)
Pfizer Laboratories Div Pfizer Inc
Usage: BOSULIF is indicated for treating chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in adults and patients aged 1 and older, whether newly diagnosed or resistant/intolerant to prior therapies. It is also used for adult patients with accelerated or blast phases of Ph+ CML who are resistant/intolerant to prior treatments.
cabometyx
(cabozantinib)
Exelixis, Inc.
Usage: CABOMETYX is indicated for advanced renal cell carcinoma (RCC), both as a monotherapy and in combination with nivolumab. It is also used for hepatocellular carcinoma (HCC) after sorafenib treatment and for locally advanced or metastatic differentiated thyroid cancer (DTC) in patients 12 and older who are radioactive iodine-refractory.
cometriq
(cabozantinib)
Exelixis, Inc.
Usage: COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
cosela
(trilaciclib)
G1 Therapeutics, Inc.
Usage: COSELA is indicated to reduce the incidence of chemotherapy-induced myelosuppression in adults prior to platinum/etoposide or topotecan regimens for extensive-stage small cell lung cancer (ES-SCLC).
cotellic
(COBIMETINIB)
Genentech, Inc.
Usage: COTELLIC® is indicated for adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations, in combination with vemurafenib. It is also indicated as a single agent for the treatment of adult patients with histiocytic neoplasms.

Kinase Inhibitor class drugs

alecensa

alunbrig

augtyro

ayvakit

balversa

bosulif

cabometyx

cometriq

cosela

cotellic